Evidence map›Paper›PMID 36409495›Full record

ArticleJAMA network open2022

Return on Investment of the COVID-19 Vaccination Campaign in New York City.

Pratha Sah, Thomas N Vilches, Seyed M Moghadas, Abhishek Pandey, Suhas Gondi, Eric C Schneider, Jesse Singer, Dave A Chokshi, Alison P Galvani

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: A cost-benefit analysis.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Pratha SahCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
Thomas N VilchesCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
Seyed M MoghadasAgent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
Abhishek PandeyCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
Suhas GondiBrigham and Women's Hospital, Boston, Massachusetts.
Eric C SchneiderThe Commonwealth Fund, New York, New York.
Jesse SingerNew York City Department of Health and Mental Hygiene, New York, New York.
Dave A ChokshiNew York University Grossman School of Medicine, New York.
Alison P GalvaniCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
Yale University · USBrigham and Women's Hospital · USNational Committee for Quality Assurance · USNew York City Department of Health and Mental Hygiene · USNew York University · USYork University · CA

Funding

CIHR OV4 – 170643
6 · The paper itself

Abstract

Importance: New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks. Objective: To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. Design, Setting, and Participants: This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. Exposures: An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. Main Outcomes and Measures: Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI. Results: During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. Conclusions and Relevance: Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic.

Indexed as

COVID-19COVID-19 VaccinesHumansImmunization ProgramsInvestmentsNew York CityCOVID-19 Vaccines

Identifiers

PMID36409495
PMCPMC9679875
OpenAlexW4309658082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.